arrow
K

Kenneth P. Olive

Columbia University Irving Medical Center
H指数:44
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer

发育和MAPK应答转录因子调控胰腺癌中特异的恶性细胞状态及相关遗传依赖性

2026-08-260
OA
Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives

莫替沙福肽、西米普利单抗、吉西他滨和纳布紫杉醇在转移性胰腺癌中的应用:一项含单细胞相关分析的单一队列2期研究

2026-08-210
OA
Combined HDAC and eIF4A inhibition: A novel epigenetic therapy for pancreatic ductal adenocarcinoma

HDAC与eIF4A联合抑制:一种新型表观遗传疗法用于治疗胰腺导管腺癌

2025-10-040
PRE
PDAC tumors from patients treated with combination MEK and autophagy inhibition reveal a treatment sensitive epithelial subtype that is enriched in murine models
2024-09-150
PRE
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer

胰腺癌中RAS-GTP抑制的肿瘤选择性活性

Nature
IF48.5
2024-04-080
OAAI
Resistance to RAS-GTP inhibition in models of pancreatic ductal adenocarcinoma arises downstream of RAS effectors

胰腺导管腺癌模型中对RAS-GTP抑制的抗性出现在RAS效应物的下游

2024-03-220
PRE
An NFATc1/SMAD3/cJUN Complex Restricted to SMAD4-Deficient Pancreatic Cancer Guides Rational Therapies
2024-02-012
PRE
Tumor-selective inhibition of active RAS in pancreatic ductal adenocarcinoma
2024-01-160
PRE
CheMo4METPANC: Combination Chemotherapy ( gemcitabine and nabpaclitaxel), chemokine (C-X-C) Motif receptor 4 inhibitor (motixafortide), and immune checkpoint blockade (cemiplimab) in METastatic treatment-naive PANCreatic adenocarcinoma
2024-01-160
PRE
Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression

肿瘤外植体阐明了驱动胰腺癌血管抑制的旁分泌SHH,WNT和VEGF信号的级联

2023-11-144
OA
A Transcriptome-Based Precision Oncology Platform for Patient-Therapy Alignment in a Diverse Set of Treatment-Resistant Malignancies
2023-04-169
OA